Subclinical inflammation is a critical hallmark of MetS, frequently indicated by increased concentrations of biomarkers including high-sensitivity C-reactive protein (hsCRP) [10], tumor necrosis factor receptor 1 (TNFR1), soluble tumor necrosis factor receptor 2 (sTNFR2), and leptin (LEP) [11]. Here, LEP is linked to metabolic syndrome.